Detection of thyroid cancer and central lymph node metastases using bevacizumab-IRDye800CW enhanced Molecular Fluorescence Guided Surgery

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 32

Inclusion Criteria

1) Age >= 18 years, eligible for surgery
2) Bethesda VI fine needle aspiration (FNA) thyroid or FNA proven
PTC/FTC/HTC/PDTC metastasis (primary or recurrence).
3) Scheduled to undergo central and/or lateral lymph node dissection with or
without thyroidectomy as discussed in the Multi-Disciplinary Thyroid Board.
4) WHO performance score of 0-2.
5) Written informed consent.
6) Mentally competent person who is able and willing to comply with study
procedures.
7) For female subjects who are of childbearing potential are premenopausal with
intact reproductive organs or are less than two years post-menopausal:
o A negative serum pregnancy test prior to receiving the tracer
o Willing to ensure that she or her partner uses effective contraception during
the trial and for 3 months thereafter.

Exclusion Criteria

1) Pregnancy or breast feeding
2) Advanced stage thyroid cancer not suitable for surgical resection
3) Medical or psychiatric conditions that compromise the patient*s ability to
give informed consent
4) Concurrent anticancer therapy (chemotherapy, radiotherapy, vaccines,
immunotherapy) delivered within the last three months prior to the start of the
treatment
5) The subject has been included previously in this study or has been injected
with another investigational medicinal product within the past six months
6) History of myocardial infarction (MI), TIA, CVA, pulmonary embolism,
uncontrolled congestive heart failure (CHF), significant liver disease,
unstable angina within 6 months prior to enrollment
7) Any significant change in their regular prescription or non-prescription
medication between 14 days and 1 day prior to IMP administration.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint<br /><br>- Fluorescent signal levels defined as Tumor-to-Background Ratio (TBR) derived<br /><br>from PTC/FTC/HTC/PDTC nodal metastasis and normal tissue to determine the<br /><br>optimal dose of Bevacizumab-800CW in patients with PTC/FTC/HTC. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints<br /><br>- Correlation of the fluorescent signal in PTC/FTC/HTC, nodal metastasis and<br /><br>normal tissue assessed by MFGS with other biological and molecular parameters<br /><br>(IHC) and the fluorescent signal assessed in the ex vivo biopsy specimens.<br /><br>- Wound bed biopsy specimen characteristics (number of positive and negative<br /><br>biopsies.<br /><br>- Distribution of bevacizumab-IRDye800CW in PTC/FTC/HTC, lymph nodes and normal<br /><br>tissue as identified by SDS-PAGE and/or ELISA and/or fluorescence microscopy.<br /><br>- Quantification of sensitivity and specificity of Bevacizumab-800CW in order<br /><br>to make a power size calculation for a possible subsequent diagnostic accuracy<br /><br>study. </p><br>